Cassandra Guarino

Cassandra Guarino

Auto-generated profile, based on publicly available information

Cassandra Guarino

College of Veterinary Medicine, Cornell University Department of Population Medicine and Diagnostic Sciences Ithaca, New York

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CGCassandra Guarino
Cassandra Guarino
ELElisabeth Larson
Elisabeth Larson
SBSusanna Babasyan
Susanna Babasyan
ARAlicia Rollins
Alicia Rollins
LJLok R. Joshi
Lok R. Joshi
BWBettina Wagner
Bettina Wagner
A serological COVID-19 Multiplex Assay was developed and validated using serum samples from convalescent patients and those collected prior to the 2020 pandemic. After initial testing of multiple potential antigens, the SARS-CoV-2 nucleocapsid protein (NP) and receptor-binding domain (RBD) of the spike protein were selected for the human COVID-19 Multiplex Assay. A comparison of synthesized and mammalian expressed RBD proteins revealed clear advantages of mammalian expression. Antibodies directed against NP strongly correlated with SARS-CoV-2 virus neutralization assay titers (rsp = 0.726), while anti-RBD correlation was moderate (rsp = 0.436). Pan-Ig, IgG, IgA, and IgM against NP and RBD antigens were evaluated on the validation sample sets. Detection of NP and RBD specific IgG and IgA had outstanding performance (AUC > 0.90) for distinguishing patients from controls, but the dynamic range of the IgG assay was substantially greater. The COVID-19 Multiplex Assay was utilized to identify seroprevalence to SARS-CoV-2 in people living in a low-incidence community in Ithaca, NY. Samples were taken from a cohort of healthy volunteers (n = 332) in early June 2020. Only two volunteers had a positive result on a COVID-19 PCR test performed prior to serum sampling. Serological testing revealed an exposure rate of at least 1.2% (NP) or as high as 5.7% (RBD), higher than the measured incidence rate of 0.16% in the county at that time. This highly sensitive and quantitative assay can be used for monitoring community exposure rates and duration of immune response following both infection and vaccination.

23 September 2021 in Frontiers in Veterinary Science
Verified
Journal Article
Open access
CGCassandra Guarino
Cassandra Guarino
TPToby Pinn-Woodcock
Toby Pinn-Woodcock
DLDavid G. Levine
David G. Levine
JMJulia Miller
Julia Miller
AJAmy L. Johnson
Amy L. Johnson
Cases of cranial nuchal bursitis associated withBorrelia burgdorferiinfection have not been thoroughly described. Here, we describe the case of a 17-year-old mare that was presented for low head carriage, dull demeanor, and resistance to haltering. Imaging supported a diagnosis of nuchal bursitis, and bursoscopy with surgical debridement of the nuchal bursa was performed.B. burgdorferiwas identified by molecular diagnostics in serial samples of the bursal fluid, with no other organisms identified. Serology revealed significant elevation in antibodies directed against OspA ofB. burgdorferi, but not the typical infection markers, OspC and OspF. Intravenous ceftiofur was administered for 80 days, and the nuchal bursa was directly injected with ceftiofur. The mare recovered and was able to return to work with no recrudescence of clinical signs over the following year to date. Infection withB. burgdorferishould be considered as a differential in cases of septic nuchal bursitis.

1 September 2025 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
BLBianca G. Landfield
Bianca G. Landfield
EAElizabeth H. Appleman
Elizabeth H. Appleman
HDHeather Daverio
Heather Daverio
CGCassandra Guarino
Cassandra Guarino
MMMary Elizabeth Moore
Mary Elizabeth Moore
GGGloria Gioia
Gloria Gioia
A 5-year-old Basenji Mix achieved extended survival with treatment for disseminated protothecosis. The dog originally presented with iridal hyperemia and ocular ultrasonographic examination revealed a mass effect. Histopathology revealed ocular protothecosis and staging confirmed disseminated protothecosis. Treatment with itraconazole and amphotericin B (AmB) infusions resulted in remission. Four years later, restaging revealed recurrence of infection in colonic biopsy samples. An extended AmB protocol was restarted for a cumulative dose of 84 mg/kg and the dog received isavuconazole based on susceptibility testing. The dog was euthanized 4 years and 8 months after initial diagnosis due to decline of neurologic status. Necropsy confirmed the presence of disseminated protothecosis in multiple arteries, multiple lymph nodes, the pituitary gland, thyroid glands, kidneys, colon, cecum, right eyelid, right eye, heart, brain, and periosteum of one bone associated with the middle ear. This report documents the extended survival of a dog with widespread disseminated protothecosis after prolonged administration of AmB.

4 November 2026 in Journal of the American Veterinary Medical Association
Verified
Journal Article
Open access
AFAmelia Frye
Amelia Frye
HKHeidi Kim
Heidi Kim
CRCionna Rosenthal
Cionna Rosenthal
CCClaudia Cobo-Angel
Claudia Cobo-Angel
YCYash Chikara
Yash Chikara
CCCasey L. Cazer
Casey L. Cazer
Objective: To determine if cefovecin administration increased the risk of third-generation cephalosporin (3GC)–resistant Escherichia coli infections in cats. Methods: In this retrospective case-case-control study, cases were cats with 3GC-susceptible or 3GC-resistant E coli infections at the Cornell University Hospital for Animals from 2009 to 2023; controls were randomly selected from all feline patients seen during the study period. Exposure data were collected via review of medical records. Direct acyclic graph–driven multivariable regression models of each potential exposure were built for each case-control grouping. Results: 36 susceptible cases (3% cefovecin treated), 14 resistant cases (21% cefovecin treated), and 72 controls (6% cefovecin treated) were identified. Resistant cases had a higher proportion of cefovecin use (21%) than susceptible cases (3%) and controls (6%), but case numbers were too low to evaluate whether cefovecin use was associated with either infection type. Most of the cats that received cefovecin (75%) were underdosed. The overall frequency of cefovecin administration was low (7%) compared to previous studies. Conclusions: Cefovecin use was less frequent than previously reported, resulting in too few cases to determine whether cefovecin use is associated with 3GC-resistant E coli infections in cats. Clinical Relevance: The sample size was too small to evaluate association between cefovecin and 3CG resistance. Based on prudent antimicrobial stewardship, veterinarians should limit cefovecin use to cases where oral antimicrobial treatment is impossible and, ideally, its use is supported by antimicrobial susceptibility testing to avoid selecting for antimicrobial resistance in treated cats. When using cefovecin, veterinarians should ensure they are administering the label-recommended 8-mg/kg dose.

1 September 2026 in Journal of Dairy Science
Verified
Journal Article
Open access
MWMatthias Josef Wieland
Matthias Josef Wieland
WFW. Flanders
W. Flanders
ASAjay Singh
Ajay Singh
JRJ. Runyan
J. Runyan
CGC. Guarino
C. Guarino
PBParminder S. Basran
Parminder S. Basran

17 November 2026 in Journal of the American Veterinary Medical Association
Verified
Journal Article
Closed access
KMKassie N. Marino
Kassie N. Marino
Nicole J. BuoteNicole J. Buote
Nicole J. Buote
JGJoshua Glass
Joshua Glass
CGCassandra Guarino
Cassandra Guarino
KSKurtis Sobkowich
Kurtis Sobkowich
CCCasey L. Cazer
Casey L. Cazer
Objective: Evaluate antimicrobial susceptibility patterns among bacterial pathogens isolated from canine pyometra cases and generate a cumulative antibiogram to inform evidence-based treatment recommendations. Methods: This observational retrospective study included canine uterine samples submitted for antimicrobial susceptibility testing to Idexx Laboratories and the Cornell University Animal Health Diagnostic Center between 2007 and 2023 in the US. Susceptibility results were interpreted according to current Clinical and Laboratory Standards Institute criteria. Cumulative antibiograms were generated with an interactive app for analysis of diagnostic antimicrobial susceptibility test data (AMR Visualizer; RShiny). Results: Across the 2 laboratories, 6,462 bacterial isolates were included. Escherichia coli was the predominant pathogen (71.7%). Among E coli isolates, poor susceptibility was observed to penicillins, β-lactam/β-lactamase inhibitor combinations, tetracyclines, and chloramphenicol. Excellent susceptibility was maintained to aminoglycosides, third-generation cephalosporins, potentiated sulfonamides, and imipenem. Most E coli isolates were susceptible-dose-dependent to fluoroquinolones and susceptible with increased exposure to intravenous amoxicillin–clavulanic acid. Conclusions: Most canine pyometras are caused by E coli . The in vitro antimicrobial susceptibility patterns of these isolates contribute to understanding resistance trends and support antimicrobial stewardship efforts. Susceptibility should be interpreted in the context of regimens used for breakpoint development. Clinical Relevance: When perioperative antimicrobial therapy of pyometras is appropriate, veterinarians can use antibiograms to assist in selecting an effective and appropriate antimicrobial before susceptibility test results are available. These antibiograms suggest that folate-pathway inhibitors could be effective empiric choices that align with antimicrobial stewardship principles. High-exposure intravenous amoxicillin–clavulanic acid could be an effective choice in regions where the product is available.